| Oct 21 |
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
|
| Oct 19 |
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
|
| Oct 10 |
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
|
| Oct 10 |
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential
|
| Sep 18 |
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
|
| Sep 16 |
Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
|
| Sep 16 |
Kyverna Therapeutics Announces Leadership Update
|
| Sep 16 |
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
|
| Aug 21 |
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
|
| Aug 13 |
Kyverna Therapeutics GAAP EPS of -$0.67
|
